Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Epigenetic dysregulation of oncogenes and tumor suppressors is fundamental to cancer development, progression, and prognosis.
• Epigenetic mechanisms are reversible, making epigenetic regulatory enzymes attractive therapeutic targets.

Purpose of the Study:

• To summarize the classification and therapeutic roles of small-molecule compounds targeting epigenetic regulatory enzymes in cancer treatment.
• To highlight the potential of natural compounds, specifically berberine and ginsenosides, in targeting epigenetic enzymes for cancer therapy.

Main Methods:

• Review and classification of small-molecule compounds targeting key epigenetic regulatory enzymes.
• Analysis of the therapeutic roles and clinical applications of these compounds in cancer.
• Focus on natural compounds like berberine and ginsenosides as epigenetic modulators.

Main Results:

• Several classes of small-molecule compounds targeting epigenetic enzymes (DNA methylases, histone modifiers, etc.) are under investigation.
• A limited number of these compounds have entered clinical trials, demonstrating some therapeutic efficacy.
• Natural compounds such as berberine and ginsenosides show potential in targeting epigenetic pathways for cancer treatment.

Conclusions:

• Targeting epigenetic regulatory enzymes represents a promising strategy for cancer therapy due to the reversible nature of epigenetic modifications.
• Further research into small-molecule and natural compound inhibitors is crucial for developing effective epigenetic therapies for various cancers.